Beyond glucose control, GLP-1 receptor agonists improve insulin sensitivity, reduce systemic inflammation, and support cardiovascular health
Regulatory backing, rising obesity rates, aging populations, and public health programs emphasizing non-injectable treatments are increasing the acceptance of oral GLP-1s
There isnt much large-scale research looking at how GLP-1 medications affect menstrual or reproductive symptoms in the general population, so more studies are needed
Those changes indicate to clinicians whether the drug is working or whether symptoms warrant further investigation, not whether the lab caught the medication itself
Setting Realistic Expectations & Emotional Health Not all patients will experience Ozempic face in the same way
Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B, Zhao X, Hai S, Li S, An Z, Dai L (2023) Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications